Ethanamine, 2,2,2-trifluoro- → HCID 58614858, compound

HRID 922936Notes

Reaction equation

HRID 922936 reaction equation
[Cl:1][C:2]1[CH:3]=[C:4]([CH:8]=[CH:9][C:10]=1[C:11](=[O:26])[NH:12][C:13]1[CH:18]=[CH:17][C:16]([Cl:19])=[C:15]([C:20]2[CH:25]=[CH:24][CH:23]=[CH:22][N:21]=2)[CH:14]=1)[C:5](O)=[O:6].[F:27][C:28]([F:32])([F:31])[CH2:29][NH2:30]>>[Cl:1][C:2]1[CH:3]=[C:4]([C:5]([NH:30][CH2:29][C:28]([F:32])([F:31])[F:27])=[O:6])[CH:8]=[CH:9][C:10]=1[C:11]([NH:12][C:13]1[CH:18]=[CH:17][C:16]([Cl:19])=[C:15]([C:20]2[CH:25]=[CH:24][CH:23]=[CH:22][N:21]=2)[CH:14]=1)=[O:26]

Participants

3

Reactant 2

HCID 9773Ethanamine, 2,2,2-trifluoro-HCID 668786053-Chloro-4-(4-chloro-3-(pyridin-2-yl)phenylcarbamoyl)benzoic acid

Product 1

HCID 58614858HCID 58614858, compound

Procedure

75 mg of 3-chloro-4-(4-chloro-3-(pyridin-2-yl)phenylcarbamoyl)benzoic acid was coupled to 2,2,2-trifluoroethylamine via Procedure G. The product was purified on reverse phase HPLC to yield 2-chloro-N1-(4-chloro-3-(pyridin-2-yl)phenyl)-N4-(2,2,2-trifluoroethyl)terephthalamide. MS (Q1) 469 (M)+.

Workup

  1. customThe product was purified on reverse phase HPLC

Sources & evidence

ORD record
ord-7061b70d41e849048a636cf7cf26ea58
Source dataset
uspto-grants-2016_03
Patent number
US09278961B2

Reaction notes

Loading…